ATE205401T1 - Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8 - Google Patents

Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8

Info

Publication number
ATE205401T1
ATE205401T1 AT98930578T AT98930578T ATE205401T1 AT E205401 T1 ATE205401 T1 AT E205401T1 AT 98930578 T AT98930578 T AT 98930578T AT 98930578 T AT98930578 T AT 98930578T AT E205401 T1 ATE205401 T1 AT E205401T1
Authority
AT
Austria
Prior art keywords
psoriasis
neutralizing antibodies
local treatment
biological activity
pharmaceutical composition
Prior art date
Application number
AT98930578T
Other languages
English (en)
Inventor
George Q W Ye
Original Assignee
Yes Biotech Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yes Biotech Lab Ltd filed Critical Yes Biotech Lab Ltd
Application granted granted Critical
Publication of ATE205401T1 publication Critical patent/ATE205401T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT98930578T 1997-06-23 1998-06-23 Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8 ATE205401T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN97112184A CN1068524C (zh) 1997-06-23 1997-06-23 一种治疗顽症牛皮癣的药物
PCT/CA1998/000604 WO1998058671A1 (en) 1997-06-23 1998-06-23 Topical treatment of psoriasis using neutralizing antibodies to il-8

Publications (1)

Publication Number Publication Date
ATE205401T1 true ATE205401T1 (de) 2001-09-15

Family

ID=5172124

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98930578T ATE205401T1 (de) 1997-06-23 1998-06-23 Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8

Country Status (9)

Country Link
US (1) US20030077283A1 (de)
EP (1) EP0991423B1 (de)
CN (1) CN1068524C (de)
AT (1) ATE205401T1 (de)
AU (1) AU727937B2 (de)
CA (1) CA2291144C (de)
DE (1) DE69801660T2 (de)
ES (1) ES2164434T3 (de)
WO (1) WO1998058671A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068319A1 (en) * 2001-03-23 2003-04-10 Menashe Bar-Eli Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-IL8 and anti-MUC18 in diverse types of tumors
FR2830449B1 (fr) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
US7282568B2 (en) 2002-12-16 2007-10-16 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
EP3689912A1 (de) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstitution in cdr
CN105132395A (zh) * 2009-03-09 2015-12-09 生物蛋白有限公司 Mirac蛋白
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
EP3597747B1 (de) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Maus-fgcgammarii-spezifischer fc-antikörper
EP3783017A1 (de) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Varianten der fc-region
CN105521489A (zh) * 2014-09-28 2016-04-27 徐州逸仕生物技术有限公司 抗人TNF-αIgY抗体及其治疗皮肤疾病的应用
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
RO130965A8 (ro) * 2015-10-16 2017-06-30 Romvac Company S.A. Producerea şi utilizarea oului hiperimun personalizat () în tratamentul psoriazisului
EP3394098A4 (de) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin-antikörper und verfahren zur verwendung
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents
JP2021510697A (ja) 2018-01-12 2021-04-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ がん処置のための坑ｉｌ−８抗体及び坑ｐｄ−１抗体を用いる組合せ治療
EP3765494A4 (de) 2018-03-15 2022-03-23 Chugai Seiyaku Kabushiki Kaisha Anti-dengue-virus-antikörper mit kreuzreaktivität gegen zika-virus und verwendungsverfahren
CN109481674A (zh) * 2018-11-14 2019-03-19 大连亚维药业有限公司 一种生物无菌乳膏药物的生产方法
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364933A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human thymocyte antigen and methods of preparing same
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
EP0563487A1 (de) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
US5707621A (en) * 1994-08-31 1998-01-13 Chugai Pharmaceutical Co., Ltd. Supression of nephritis-induced protein excretion by anti-IL-8
JPH08277299A (ja) * 1995-04-06 1996-10-22 Fujirebio Inc 抗ｉｌ−８抗体、抗ｉｌ−８モノクローナル抗体を産生するハイブリドーマ及び該抗体を用いたｉｌ−８の測定方法
ID21676A (id) * 1996-11-08 1999-07-08 Idec Pharma Corp Identifikasi interaksi-interaksi ikatan yang khas antara antibodi-antibodi dan antigen-antigen pembantu rangsangan b7.1 dan b7.2 manusia tertentu

Also Published As

Publication number Publication date
DE69801660D1 (de) 2001-10-18
CA2291144C (en) 2001-07-03
AU8096298A (en) 1999-01-04
EP0991423B1 (de) 2001-09-12
CN1068524C (zh) 2001-07-18
ES2164434T3 (es) 2002-02-16
DE69801660T2 (de) 2002-06-06
WO1998058671A1 (en) 1998-12-30
AU727937B2 (en) 2001-01-04
CN1203105A (zh) 1998-12-30
US20030077283A1 (en) 2003-04-24
EP0991423A1 (de) 2000-04-12
CA2291144A1 (en) 1998-12-30

Similar Documents

Publication Publication Date Title
ATE205401T1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
DE60033530D1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
DE69940975D1 (de) Verwendung von glp-1 oder analoge zur behandlung von schlaganfall
DE69738615D1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
BR9305783A (pt) Processo para preparar grânulos dispersiveis em água e grânulos dispersíveis em água
AR004170A1 (es) Peptidos ciclicos semisinteticos, utiles como inhibidores de hongos y parasitos; procedimiento para prepararlos, formulaciones que los incluyeny metodo para tratar infecciones fungicas con aplicacion de dichas formulaciones
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
NO995843L (no) Farmasoeytisk preparat omfattende vWF-propeptid
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
DE69132575T2 (de) Sampangin-derivate zur verwendung als antimykotische und antimykobakterielle wirkstoffe
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
NZ503372A (en) Chemical supplementation of bone by exposing bone to a therapeutic compound and applying a potential difference across the bone or tissue
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
AP9801416A0 (en) Method Of treating a plant disease.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE59406934D1 (de) Neue verwendung von equisetum
DK0820308T3 (da) Konjugat til behandling af inflammatoriske sygdomme
DE69831336D1 (de) Tazaroten und uvb-phototherapie zur behandlung von psoriasis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties